Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01452594 · ClinicalTrials.gov registry record
Analysis of Diphenylcyclopropenone (DPCP) in Normals
A clinical trial, sponsored by Rockefeller University.
- Completed
- Registry status
- 30
- Enrollment target
NCT01452594: Completed study, sponsored by Rockefeller University.
NCT01452594 is a clinical trial that has completed, run by Rockefeller University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01452594 has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The drug diphenylcyclopropenone, or DPCP, modifies the immune system and has been shown to be effective in treating certain kinds of cancer. This study hopes to improve our understanding of how this drug helps create an effective immune response.
Interventions
- DRUG Placebo
- DRUG Diphenylcyclopropenone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-09 |
What the finished NCT01452594 record still lists
NCT01452594 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01452594 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01452594 about?
NCT01452594 is a clinical study titled "Analysis of Diphenylcyclopropenone (DPCP) in Normals". The drug diphenylcyclopropenone, or DPCP, modifies the immune system and has been shown to be effective in treating certain kinds of cancer. This study hopes to improve our understanding of how this drug helps create an effective immune response.
What is the current status of trial NCT01452594?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2011-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01452594?
The interventions under investigation include: Placebo (DRUG), Diphenylcyclopropenone (DRUG).
Who is sponsoring clinical trial NCT01452594?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia